V. Cottin (Lyon, France), S. Ramjug (Altrincham, United Kingdom)
Lung vessel morphology changes with airway obstruction
M. Pienn (Graz, Austria), T. Fero (Heidelberg, Germany), G. Kovacs (Graz, Austria), H. Olschewski (Graz, Austria), J. Biederer (Heidelberg, Germany), B. Jobst (Heidelberg, Germany)
|   |
LSC - 2020 - GCN2 signalling is dysregulated in pulmonary fibrosis
D. Santos Ribeiro (Auderghem, Belgium)
| |
Risk assessment in severe pulmonary hypertension due to interstitial lung disease
A. Yogeswaran (Giessen, Germany), M. Faber (Giessen, Germany), K. Tello (Giessen, Germany), N. Sommer (Giessen, Germany), H. Ghofrani (Giessen, Germany), W. Seeger (Giessen, Germany), M. Richter (Giessen, Germany), H. Gall (Giessen, Germany)
| |
Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension
R. Lewis (Sheffield (South Yorkshire), United Kingdom), A. Thompson (Sheffield (South Yorkshire), United Kingdom), C. Billings (Sheffield (South Yorkshire), United Kingdom), A. Charalampopoulos (Sheffield (South Yorkshire), United Kingdom), C. Elliot (Sheffield (South Yorkshire), United Kingdom), N. Hamilton (Sheffield (South Yorkshire), United Kingdom), C. Hill (Sheffield (South Yorkshire), United Kingdom), J. Hurdman (Sheffield (South Yorkshire), United Kingdom), S. Rajaram (Sheffield (South Yorkshire), United Kingdom), I. Sabroe (Sheffield (South Yorkshire), United Kingdom), A. Swift (Sheffield (South Yorkshire), United Kingdom), D. Kiely (Sheffield (South Yorkshire), United Kingdom), R. Condliffe (Sheffield (South Yorkshire), United Kingdom)
| |
Pulmoanry hypertension is a negative prognostic factot of long term survival in patients with idiopathic pulmonary fibrosis after lung transplantation
Y. Adir (Haifa, Israel), M. Shay Amor (Petah Tiqva, Israel), S. Schneer (Haifa, Israel), D. Rosengarten (Petah Tiqva, Israel), Y. Shostak (Haifa, Israel), M. Kramer (Petah Tiqva, Israel)
| |
Treatment of severe pulmonary hypertension secondary to chronic lung disease: A multicentre study.
V. Prudencio Ribera (Madrid, Spain), A. Aurtenetxe Pérez (Bilbao, Spain), M. Coronel (Corrientes, Argentina), V. Pérez González (Madrid, Spain), F. Mazo Etxaniz (Bilbao, Spain), M. Velázquez Martín (Madrid, Spain), C. Quezada Loaiza (Madrid, Spain), P. Escribano Subías (Madrid, Spain)
| |
Impact of borderline (BL) pulmonary hypertension (PH) in chronic lung diseases (CLD).
L. Piccari On Behalf Of The Rehar Registry (Barcelona, Spain), P. Vitulo (Palermo, Italy), S. Wort (London, United Kingdom), F. Meloni (Pavia, Italy), A. Bertani (Palermo, Italy), I. Blanco (Barcelona, Spain), L. Price (London, United Kingdom), E. Salvaterra (Pavia, Italy), M. Beretta (Palermo, Italy), V. Pérez Rodríguez (Madrid, Spain), C. Mc Cabe (London, United Kingdom), E. Cattaneo (Pavia, Italy), A. Callari (Palermo, Italy), M. López Meseguer (Barcelona, Spain), L. Scelsi (Pavia, Italy), D. Rodríguez (Barcelona, Spain), J. Barberà (Barcelona, Spain), L. Martino (Palermo, Italy), F. Tuzzolino (Palermo, Italy)
| |
Exercise hemodynamics in patients with COPD
T. Sassmann (Graz, Austria), P. Douschan (Graz, Austria), V. Foris (Graz, Austria), A. Avian (Graz, Austria), P. Rosenstock (Graz, Austria), K. Zeder (Graz, Austria), G. Bachmaier (Graz, Austria), H. Olschewski (Graz, Austria), G. Kovacs (Graz, Austria)
| |
Resistive and dynamic exercise stress testing in COPD and IPF candidates to lung transplantation: role of the pulmonary arterial stiffness
E. Domingo (Barcelona, Spain), J. Grignola (Montevideo, Uruguay), C. Bravo (Barcelona, Spain), M. López Messeguer (Barcelona, Spain), P. Suasnavar (Barcelona, Spain), A. Roman (Barcelona, Spain)
| |
Different response to pulmonay vasoactive therapy in pulmonary hypertension due to lung diseases (group III PH) Report from a pneumology based PH center
K. Heinig-Menhard (Gauting, Germany), C. Stoleriu (Gauting, Germany), M. Neiswirth (Gauting, Germany), J. Behr (Gauting, Germany), R. Göres (Munich, Germany), W. Gesierich (Munich, Germany), E. Silbernagel (Salzburg, Austria), F. Reichenberger (Munich, Germany)
| |
Identifying pulmonary hypertension in newly recognized interstitial lung diseases – a role of new scoring system
M. Sobiecka (Warsaw, Poland), K. Lewandowska (Warsaw, Poland), J. Kober (Warsaw, Poland), M. Franczuk (Warsaw, Poland), A. Skoczylas (Warsaw, Poland), W. Tomkowski (Warsaw, Poland), J. Kus (Warsaw, Poland), M. Szturmowicz (Warsaw, Poland)
| |
Different definitions of pulmonary hypertension in interstitial lung disease: a prognostic evaluation.
T. Sato (Seto, Japan), T. Furukawa (Nagoya, Japan), R. Teramachi (Nagoya, Japan), Y. Yamano (Seto, Japan), T. Yokoyama (Seto, Japan), T. Matsuda (Seto, Japan), K. Kataoka (Seto, Japan), T. Kimura (Seto, Japan), Y. Kondoh (Seto, Japan)
| |
Pulmonary hypertension associated with definitive and probable usual interstitial pneumonia
G. Nekludova (Moscow, Russian Federation), A. Cherniak (Moscow, Russian Federation), Z. Merhoeva (Moscow, Russian Federation), N. Tsareva (Moscow, Russian Federation), Z. Naumenko (Moscow, Russian Federation), S. Avdeev (Moscow, Russian Federation)
| |
Phenotype of patients with severe pulmonary hypertension secondary to chronic obstructive pulmonary disease: A multicentre study.
V. Prudencio Ribera (Madrid, Spain), A. Aurtenetxe Pérez (Bilbao, Spain), M. Coronel (Corrientes, Argentina), C. Pérez-Olivares Delgado (Madrid, Spain), M. Cristo Ropero (Madrid, Spain), V. Pérez González (Madrid, Spain), F. Mazo Etxaniz (Bilbao, Spain), C. Quezada Loaiza (Madrid, Spain), P. Escribano Subías (Madrid, Spain)
| |
The association of diuretics treatment with hospitalization rates of patients with chronic obstructive pulmonary disease and pulmonary hypertension: a population-based study
E. Jureviciene (Vilnius, Lithuania), R. Puronaite (Vilnius, Lithuania), V. Sudmantaite (Vilnius, Lithuania), E. Danila (Vilnius, Lithuania)
| |
Association of FVC/DLCO with pulmonary hypertension risk and interstitial disease in systemic sclerosis patients
E. Vallejos (Ciudad Autónoma Buenos Aires, Argentina), J. Martinez (Ciudad Autónoma Buenos Aires, Argentina), F. Cabrera (Ciudad Autónoma Buenos Aires, Argentina), N. Mastandrea (Ciudad Autónoma Buenos Aires, Argentina), M. Pertuz (Ciudad Autónoma Buenos Aires, Argentina), Z. Marengo (Ciudad Autónoma Buenos Aires, Argentina), M. López Meiller (Ciudad Autónoma Buenos Aires, Argentina), V. Volberg (Ciudad Autónoma Buenos Aires, Argentina), R. Gómez Tejada (Ciudad Autónoma Buenos Aires, Argentina)
| |
Response to PAH specific therapy in systemic sclerosis patients with extensive parenchymal changes and pulmonary hypertension
S. Erol (Ankara, Turkey), A. Bostanoglu (Ankara, Turkey), O. Isik (Ankara, Turkey), K. Turkel (Ankara, Turkey), Z. Oner (Ankara, Turkey), O. Ozdemir Kumbasar (Ankara, Turkey), C. Tulunay Kaya (Ankara, Turkey), T. Sayin (Ankara, Turkey)
| |
Sarcoidosis-associated Pulmonary Hypertension: A London Cohort
L. Price (London, United Kingdom), V. Kouranos (London, United Kingdom), K. Dimopoulos (London, United Kingdom), C. Mccabe (London, United Kingdom), A. Kempny (London, United Kingdom), L. Price (London, United Kingdom), G. Costola (London, United Kingdom), C. Harries (London, United Kingdom), E. Renzoni (London, United Kingdom), P. Molyneaux (London, United Kingdom), M. Kokosi (London, United Kingdom), T. Maher (London, United Kingdom), F. Chua (London, United Kingdom), P. George (London, United Kingdom), A. Wells (London, United Kingdom), S. Wort (London, United Kingdom)
| |
Effect of Pulmonary Hypertension in exercise tolerance in patients with Chronic Obstructive Pulmonary Disease: A systematic review and meta-analysis
R. Torres-Castro (Barcelona, Spain), E. Gimeno-Santos (Barcelona, Spain), J. Vilaró (Barcelona, Spain), M. Roqué I Figuls (Barcelona, Spain), J. Moisés (Barcelona, Spain), J. Barberà (Barcelona; Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Madrid, Spain., Spain), I. Blanco (Barcelona; Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Madrid, Spain., Spain)
| |